| CASE REPORT |
|
| Year : 2019 | Volume
: 2
| Issue : 1 | Page : 26-28 |
|
|
Escalating erythrocytosis after start of pazopanib-treatment in metastatic renal cell carcinoma
Pepijn M Langbroek, Marco B Polée, Hiltje de Graaf
Department of Internal Medicine, Medical Centre Leeuwarden (MCL), Leeuwarden, The Netherlands
Correspondence Address:
Drs. Pepijn M Langbroek
Department of Internal Medicine, Polikliniek Interne Geneeskunde, Treant Zorggroep Ziekenhuislocatie Scheper, Postbus 30002, 7800 RA Emmen
The Netherlands
 Source of Support: None, Conflict of Interest: None  | 2 |
DOI: 10.4103/JCO.JCO_24_18
|
|
|
Renal cell carcinoma accounts for 2% of adult malignancies in the Netherlands. Metastatic disease is often treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as pazopanib. This treatment is known to cause a slight increase in hemoglobin level during treatment. We present a patient who was diagnosed with metastatic renal cell carcinoma during analyses for erythrocytosis and who developed a further rise in hemoglobin level to 13.2 mmol/L 2 weeks after starting pazopanib treatment. Multiple phlebotomies were necessary before symptoms improved. Preexistent erythrocytosis should be considered as a risk factor for symptomatic erythrocytosis during pazopanib treatment and warrants timely laboratory follow-up and phlebotomies if indicated. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
